C-2GPETechBio AI, in-silico discovery, molecular design
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop a therapeutic approach for cardiovascular disease, including clearing small dense LDL from circulation.
Therapeutic discovery and molecular design using iMetabolic Biopharma's TechBio AI / iPlatform approach.
NHLBI Notice of Award received for NIH application titled "Therapeutic Approach to Clear sdLDL from Circulation" on 2024-09-15.
Develop a therapeutic program for HLP3 within the company's obesity-related comorbidity pipeline.
Therapeutic discovery and molecular design using iMetabolic Biopharma's TechBio AI / iPlatform approach.
Listed by the company as a pipeline program.
Develop a therapeutic program for metabolic disease and obesity-related comorbidities.
Therapeutic discovery and molecular design using iMetabolic Biopharma's TechBio AI / iPlatform approach.
Listed by the company as a pipeline program.
Develop a therapeutic program for neurodegenerative disease, with site analysis keywords indicating ApoE4 relevance.
Therapeutic discovery and molecular design using iMetabolic Biopharma's TechBio AI / iPlatform approach.
Listed by the company as a pipeline program.
Improve therapeutic discovery and development for obesity-related cardiometabolic, cardiovascular, and neurodegenerative diseases.
Proprietary TechBio AI using in-silico therapeutic discovery and molecular design.
Company describes the platform as its core computational approach for listed therapeutic programs.